REVB
Revelation Biosciences, Inc.
0.9825
+0.0225+2.34%
Dec 16, 4:00:00 PM EST

Upcoming Earnings 

Report date
≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap
5.82M
P/E (TTM)
0.01
Basic EPS (TTM)
81.25
Dividend Yield
0%

Recent Filings

About 

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

CEO
Mr. James M. Rolke
IPO
11/17/2020
Employees
8
Sector
Healthcare
Industry
Biotechnology